HUP0104439A3 - Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof - Google Patents

Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Info

Publication number
HUP0104439A3
HUP0104439A3 HU0104439A HUP0104439A HUP0104439A3 HU P0104439 A3 HUP0104439 A3 HU P0104439A3 HU 0104439 A HU0104439 A HU 0104439A HU P0104439 A HUP0104439 A HU P0104439A HU P0104439 A3 HUP0104439 A3 HU P0104439A3
Authority
HU
Hungary
Prior art keywords
corticosteroids
pharmaceutical compositions
modulating responsiveness
responsiveness
modulating
Prior art date
Application number
HU0104439A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0104439A2 publication Critical patent/HUP0104439A2/hu
Publication of HUP0104439A3 publication Critical patent/HUP0104439A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0104439A 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof HUP0104439A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (fr) 1997-03-18 1998-03-12 Procedes et compositions permettant de moduler la sensibilite aux corticosteroides

Publications (2)

Publication Number Publication Date
HUP0104439A2 HUP0104439A2 (hu) 2002-04-29
HUP0104439A3 true HUP0104439A3 (en) 2002-08-28

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104439A HUP0104439A3 (en) 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Country Status (20)

Country Link
EP (1) EP0998300A1 (fr)
JP (1) JP2002504091A (fr)
KR (1) KR20000076420A (fr)
CN (1) CN1269722A (fr)
AU (1) AU734756B2 (fr)
BG (1) BG103808A (fr)
BR (1) BR9810409A (fr)
CA (1) CA2282845A1 (fr)
DE (1) DE998300T1 (fr)
ES (1) ES2146192T1 (fr)
HU (1) HUP0104439A3 (fr)
ID (1) ID22975A (fr)
IL (1) IL131815A0 (fr)
NO (1) NO994506L (fr)
NZ (1) NZ337769A (fr)
PL (1) PL336464A1 (fr)
SI (1) SI20110A (fr)
SK (1) SK122199A3 (fr)
TR (1) TR199902615T2 (fr)
WO (1) WO1998041232A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE69825976T2 (de) * 1997-10-31 2005-09-01 Wyeth Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
EP1516630A3 (fr) * 1997-10-31 2006-05-03 Wyeth Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes
WO1999025737A1 (fr) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions et procedes de traitement de maladies autoimmunes a l'aide d'un anticorps monoclonal se liant a la chaine interleukine-12 beta2
CA2323439A1 (fr) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptides inhibiteurs de caspase et leur utilisation
EP1140206A4 (fr) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation Vaccin base sur un facteur d'induction de l'interferon gamma et utilisation de ce vaccin destine a conferer une immunite de protection contre la sclerose multiple
CA2353520C (fr) * 1998-12-09 2006-04-25 Protein Design Labs, Inc. Modele animal du psoriasis destine a la prevention et au traitement du psoriasis humain
CN1346344A (zh) 1999-03-16 2002-04-24 西托维亚公司 取代的2-氨基苯甲酰胺天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其应用
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
JP2002541237A (ja) 1999-04-09 2002-12-03 サイトビア インコーポレイテッド カスパーゼインヒビターおよびその使用
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
WO2001019373A2 (fr) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
TW201305214A (zh) 2000-02-10 2013-02-01 Abbott Gmbh & Co Kg 與人類間白素-18結合之抗體,及其製法及用途
JP2003535148A (ja) * 2000-06-06 2003-11-25 グラクソ グループ リミテッド 癌の治療方法
WO2001097815A2 (fr) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Utilisation de glucocorticosteroides pour la production d'un medicament servant a traiter l'alopecie
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (fr) * 2000-09-15 2002-04-24 Warner-Lambert Company Composition pharmaceutique pour la prévention ou le traitement de maladies associées à un excès de production d' IL-12
EP1188438A1 (fr) * 2000-09-15 2002-03-20 Warner-Lambert Company Compositions pharmaceutiques pour la prévention ou le traitement de maladies associées à un excès de production de l' IL-12
UA80676C2 (en) * 2001-01-29 2007-10-25 Applied Research Systems Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy
ATE451930T1 (de) * 2001-05-16 2010-01-15 Yeda Res & Dev Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1448205B1 (fr) * 2001-10-05 2011-03-23 Zalicus Inc. Combinaisons permettant le traitement des troubles immunoinflammatoires
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2004030618A2 (fr) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methodes et reactifs destines au traitement de maladies et de troubles associes a des niveaux accrus de cytokines pro-inflammatoires
WO2004028545A1 (fr) * 2002-09-25 2004-04-08 Astrazeneca Ab Combinaison d'un agoniste $g(b)2 a action prolongee et d'un glucocorticosteroide dans le traitement de maladies fibrotiques
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (fr) * 2004-05-17 2005-11-24 Keio University Composition médicinale et procédé thérapeutique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005264453B2 (en) * 2004-07-16 2011-07-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (fr) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Traitements prophylactiques ou therapeutiques de maladie chronique de la peau
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
EP2274333A4 (fr) 2008-03-18 2011-06-15 Abbott Lab Procédé de traitement de psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2646012A4 (fr) 2010-11-24 2014-12-10 Neothetics Inc Formulations monothérapeutiques d'agonistes bêta sélectifs, lipophiles et à action prolongée, et procédés de traitement cosmétique de l'adiposité et du renflement de la silhouette
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
FR2651678B1 (fr) * 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NZ306281A (en) * 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate

Also Published As

Publication number Publication date
KR20000076420A (ko) 2000-12-26
WO1998041232A2 (fr) 1998-09-24
ID22975A (id) 1999-12-23
JP2002504091A (ja) 2002-02-05
NO994506L (no) 1999-11-17
WO1998041232A3 (fr) 2000-10-05
CN1269722A (zh) 2000-10-11
NO994506D0 (no) 1999-09-17
PL336464A1 (en) 2000-06-19
HUP0104439A2 (hu) 2002-04-29
AU734756B2 (en) 2001-06-21
IL131815A0 (en) 2001-03-19
AU6760498A (en) 1998-10-12
NZ337769A (en) 2002-09-27
EP0998300A1 (fr) 2000-05-10
ES2146192T1 (es) 2000-08-01
SK122199A3 (en) 2000-12-11
BG103808A (en) 2000-07-31
CA2282845A1 (fr) 1998-09-24
SI20110A (sl) 2000-06-30
DE998300T1 (de) 2001-03-01
BR9810409A (pt) 2000-08-22
TR199902615T2 (xx) 2000-03-21

Similar Documents

Publication Publication Date Title
HUP0104439A3 (en) Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
PL322494A1 (en) Compounds and compositions intended to provide active substances
HUP0003761A2 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
HUP0101999A3 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
IL114229A0 (en) Compositions for applying active substances to or through the skin
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
IL131319A0 (en) 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HUP9900424A2 (hu) Tiazolil-benzfurán-származékok és a vegyületeket tartalmazó gyógyászati készítmények
IL136937A0 (en) τ-GLUTAMYL AND β-ASPARTYL CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PL330880A1 (en) Liquid antiperspirant and deodorising composition
HUP0002510A3 (en) Tetrazole derivatives and pharmaceutical compositions containing them
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
AU7127600A (en) Methods and compositions for modulating responsiveness to corticosteroids
HUP9901452A3 (en) Bicyclic-aromatic compounds and pharmaceutical compositions containing them
PL330396A1 (en) Solid cosmetic composition and application thereof
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
HUP0001858A3 (en) Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds
AP9600866A0 (en) Benzamine derivative compositions containing said derivative and use thereof
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
PL330395A1 (en) Solid cosmetic composition and application thereof